332 related articles for article (PubMed ID: 7995947)
1. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
[TBL] [Abstract][Full Text] [Related]
2. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
3. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
[TBL] [Abstract][Full Text] [Related]
5. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
Whiteside TL; Chikamatsu K; Nagashima S; Okada K
Anticancer Res; 1996; 16(4C):2357-64. PubMed ID: 8816835
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
8. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
9. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
Sacchi M; Johnson JT; Whiteside TL; Cortesina G
Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
[TBL] [Abstract][Full Text] [Related]
11. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
[TBL] [Abstract][Full Text] [Related]
12. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency.
Hill LL; Perussia B; McCue PA; Korngold R
Cancer Res; 1994 Feb; 54(3):763-70. PubMed ID: 8306339
[TBL] [Abstract][Full Text] [Related]
13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor activity of adherent LAK cells (A-LAK) in a model of squamous carcinoma of the head and neck].
Sacchi M; Galeazzi E; Johnson JT; Cavalot AL; Cortesina G
Acta Otorhinolaryngol Ital; 1991; 11(4):405-15. PubMed ID: 1792895
[TBL] [Abstract][Full Text] [Related]
15. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity.
Matsui M; Kishida T; Nakano H; Yoshimoto K; Shin-Ya M; Shimada T; Nakai S; Imanishi J; Yoshimoto T; Hisa Y; Mazda O
Cancer Res; 2009 Mar; 69(6):2523-30. PubMed ID: 19244121
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
18. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
20. The biology of human natural killer cells.
Whiteside TL; Herberman RB
Ann Ist Super Sanita; 1990; 26(3-4):335-48. PubMed ID: 2091502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
